An excerpt from BioMarin's investor page dated from the 3rd of August 2015, about the results of the Phase 2 clinical study.

A summary of the four drugs under development at the moment for achondroplasia.

News about a potential treatment for achondroplasia, meclizine, being tested by a Japanese team, from the ICCBH 2015 in Salzburg.

Comments by Mark Schoenebaum, Biotech/Pharma analyst since 2000 MD, Johns Hopkins School of Medicine, 2000 BA, Indiana University, 1995 with 6 key tidbits about BMN-111 (vosoritide).

BioMarin announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111. now known as vosoritide, a drug in development for achondroplasia.

News on the BMN-111 Phase II clinical trial by BioMarin.